General
Preferred name
ALOSETRON
Synonyms
Alosetron (D3 Hydrochloride) ()
Alosetron ((Z)-2-butenedioate) ()
GR-68755C D3 ()
GR 68755 ((Z)-2-butenedioate) ()
GR 68755X ((Z)-2-butenedioate) ()
Lotronex ()
GR 68755C ()
GR 68755 ()
GR 68755X ()
ALOSETRON HYDROCHLORIDE ()
Alosetron HCl ()
Alosetron (Hydrochloride) ()
GR 68755 (Hydrochloride) ()
GR 68755X (Hydrochloride) ()
GR 68755C, GR 68755, GR 68755X, Lotronex, GR-68755, GR68755 ()
Alosetron Hydrochloride(1:X) ()
Alosetron (Z)-2-butenedioate ()
Alosetron (hydrochoride) ()
Lotrpnex ()
GR-68755C ()
A03AE01 ()
P&D ID
PD009613
CAS
122852-69-1
122852-42-0
132414-02-9
122852-43-1
Tags
available
drug
Approved by
FDA
First approval
2000
Drug indication
Irritable bowel syndrome
Drug Status
approved
withdrawn
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Having been withdrawn by the manufacturer in 2000 following reports of severe adverse effects, the FDA approved a supplemental new drug application (2002) which allows remarketing of the drug, but under conditions of restricted use.
(GtoPdb)
DESCRIPTION
The hydrochloride salt form of Alosetron, a 5HT3-receptor antagonist, could be used against bowel syndrome.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Alosetron hydrochloride (GR 68755) is the hydrochloride salt form of alosetron, a potent and selective 5-HT3 receptor antagonist. Alosetron blocks the actions of serotonin at 5-HT3 sites in the peripheral nervous system, particularly on enteric and nociceptive sensory neurons, thereby affecting the regulation of visceral pain, decreasing gastrointestinal contraction and motility, and decreasing gastrointestinal secretions.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Alosetron, an effective 5-HT3 receptor antagonist, could be commonly used against irritable bowel syndrome.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
The maleic acid salt form of Alosetron which is an effective 5-HT3 receptor antagonist and could be commonly used against irritable bowel syndrome.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
32
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
63
Molecular Weight
294.15
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
4
Aromatic Ring Count
3
cLogP
2.41
TPSA
53.92
Fraction CSP3
0.29
Chiral centers
0.0
Largest ring
6.0
QED
0.79
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
5-HT Receptor
5-HT3
HTR3A
5-HT3 antagonist
Pathway
Neuronal Signaling
GPCR/G protein
Neuroscience
MOA
serotonin receptor antagonist
ATC
A03AE01
Toxicity type
gastrointestinal
Therapeutic Class
Gastrointestinal Agents
Solubility
10 mM in DMSO
Recommended Cell Concentration
10 nM
Source data
